|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| == '''What is Eligard?''' ==
| | #REDIRECT [[Leuprorelin]] |
|
| |
|
| * '''Eligard''' ([[leuprolide acetate]]) is '''a gonadotropin releasing hormone (GnRH) agonist''' used for the [[palliative]] treatment of advanced [[prostate cancer]].
| | {{redr| |
| | | {{R from trade name}} |
| [[File:Leuprorelin.svg|thumb|Leuprorelin]]
| | }} |
| [[File:Leuprorelin ball-and-stick.png|thumb|Leuprorelin ball-and-stick]]
| |
| | |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v/v=ongS6p-ALOs
| |
| embed_source_url=http://www.youtube.com/v/v=ongS6p-ALOs
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| | |
| == '''What are the uses of this medicine?''' ==
| |
| | |
| * '''Eligard''' ([[leuprolide acetate]]) is used for the [[palliative]] treatment of advanced [[prostate cancer]].
| |
| | |
| | |
| == '''How does this medicine work?''' ==
| |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v/v=80igdEvCVKY
| |
| embed_source_url=http://www.youtube.com/v/v=80igdEvCVKY
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| * Leuprolide acetate, '''a gonadotropin releasing hormone (GnRH) agonist''', acts as '''a potent inhibitor of gonadotropin secretion''' when given continuously in therapeutic doses.
| |
| * In humans, administration of leuprolide acetate results in an '''initial increase in circulating levels of [[luteinizing hormone]] (LH) and [[follicle stimulating hormone]] (FSH)''', leading to a transient increase in levels of the gonadal steroids ([[testosterone]] and [[dihydrotestosterone]] in males, and [[estrone]] and [[estradiol]] in [[premenopausal]] females).
| |
| * However, '''continuous administration of leuprolide acetate results in decreased levels of LH and FSH'''.
| |
| * These decreases occur within two to four weeks after initiation of treatment.
| |
| * Long-term studies have shown that continuation of therapy with leuprolide acetate maintains testosterone below the castrate level for up to seven years.
| |
| * This may stop the growth of cancer cells that need testosterone to grow.
| |
| | |
| | |
| == '''Who Should Not Use this medicine ?''' ==
| |
| | |
| This medicine cannot be used in patients with:
| |
| * [[hypersensitivity]] to GnRH, GnRH agonist analogs or any of the components of Eligard
| |
| | |
| | |
| == '''What drug interactions can this medicine cause?''' ==
| |
| | |
| * No pharmacokinetic drug-drug interaction studies were conducted with Eligard.
| |
| | |
| | |
| == '''Is this medicine FDA approved?''' ==
| |
| | |
| * Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985.
| |
| | |
| | |
| == '''How should this medicine be used?''' ==
| |
| | |
| '''Recommended dosage:'''
| |
| * 7.5 mg subcutaneously every month.
| |
| * 22.5 mg subcutaneously every 3 months.
| |
| * 30 mg subcutaneously every 4 months.
| |
| * 45 mg subcutaneously every 6 months.
| |
| | |
| '''Administration:'''
| |
| * Eligard is administered [[subcutaneously]] and provides continuous release of leuprolide acetate over a one-, three-, four-, or six-month treatment period.
| |
| | |
| | |
| == '''What are the dosage forms and brand names of this medicine?''' ==
| |
| | |
| This medicine is available in fallowing doasage form:
| |
| * As Injectable suspension: 7.5 mg
| |
| * Injectable suspension: 22.5 mg
| |
| * Injectable suspension: 30 mg
| |
| * Injectable suspension: 45 mg
| |
| | |
| This medicine is available in fallowing brand namesː
| |
| * '''Eligard'''
| |
| | |
| | |
| =='''What side effects can this medication cause?'''==
| |
| | |
| The most common side effects of this medicine include:
| |
| * [[Malaise]]
| |
| * [[fatigue]]
| |
| * [[hot flashes]]/sweats
| |
| * [[testicular atrophy]]
| |
| * decreased [[bone density]]
| |
| * rare cases of pituitary [[apoplexy]]
| |
| | |
| | |
| ==''' What special precautions should I follow?''' ==
| |
| | |
| * Transient increase in serum levels of [[testosterone]] during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, [[neuropathy]], [[hematuria]], bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
| |
| * [[Hyperglycemia]] and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice.
| |
| * Response to Eligard® should be monitored by periodic measurement of serum concentrations of [[testosterone]] and [[prostate specific antigen]]. In the majority of patients, testosterone levels increased above Baseline during the first week, declining thereafter to Baseline levels or below by the end of the second or third week.
| |
| * Increased risk of [[myocardial infarction]], sudden [[cardiac death]] and [[stroke]] has been reported in men. Monitor for cardiovascular disease and manage according to current clinical practice.
| |
| * Androgen deprivation therapy may prolong the QT interval. Consider risks and benefits.
| |
| * Based on findings in animal studies and mechanism of action, leuprolide acetate may cause fetal harm when administered to a pregnant woman. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
| |
| * [[Convulsions]] have been observed in patients with or without a history of predisposing factors. Manage convulsions according to the current clinical practice.
| |
| | |
| | |
| == '''What to do in case of emergency/overdose?''' ==
| |
| | |
| Symptoms of overdosage may include:
| |
| * {{overdose}}
| |
| | |
| '''Management of overdosage:'''
| |
| | |
| | |
| == '''Can this medicine be used in pregnancy?''' ==
| |
| | |
| * Based on findings in animal studies and mechanism of action, Eligard may cause fetal harm when administered to a pregnant woman.
| |
| * Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.
| |
| | |
| | |
| =='''Can this medicine be used in children?'''==
| |
| | |
| * The safety and effectiveness of Eligard in pediatric patients have not been established.
| |
| | |
| | |
| == '''What are the active and inactive ingredients in this medicine?''' ==
| |
| | |
| '''Active ingredient:'''
| |
| * LEUPROLIDE ACETATE
| |
| | |
| '''Inactive ingredients:'''
| |
| * METHYL PYRROLIDONE
| |
| * POLY(DL-LACTIC-CO-GLYCOLIC ACID)
| |
| | |
| | |
| == '''Who manufactures and distributes this medicine?''' ==
| |
| | |
| '''Manufactured by:'''
| |
| * [[Tolmar, Inc.|Tolmar, Inc]].
| |
| * Fort Collins, CO
| |
| * for: Tolmar Therapeutics, Inc.
| |
| * Fort Collins, CO
| |
| | |
| '''Distributed by:'''
| |
| * Tolmar Pharmaceuticals, Inc.
| |
| * Fort Collins, CO
| |
| | |
| | |
| == '''What should I know about storage and disposal of this medication?''' ==
| |
| | |
| * Store at 2 - 8 °C (35.6 - 46.4 °F)
| |
| * Once outside the refrigerator this product may be stored in its original packaging at room temperature 15 – 30 °C (59 – 86 °F) for up to eight weeks prior to mixing and administration.
| |
| | |
| | |
| | |
| {{coststubd}}
| |
| {{GnRH and gonadotropins}} | |
| {{GnRH and gonadotropin receptor modulators}}
| |
| {{Portal bar|Medicine}}
| |
| [[Category:GnRH agonists]]
| |
| [[Category:Hormonal antineoplastic drugs]]
| |
| [[Category:Peptides]]
| |
| [[Category:Puberty blockers]]
| |
| [[Category:Feminizing hormone therapy]]
| |
